- Home
- MNPR vs KOPN Comparison
MNPR vs KOPN Comparison
Compare MNPR & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | KOPN |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 396.8M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MNPR | KOPN |
|---|---|---|
| Price | $62.74 | $5.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $107.00 | $4.69 |
| AVG Volume (30 Days) | 164.9K | ★ 12.6M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.99 | ★ 103.03 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,530,311.00 |
| Revenue This Year | N/A | $50.07 |
| Revenue Next Year | N/A | $33.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 46.53 |
| 52 Week Low | $28.40 | $1.23 |
| 52 Week High | $105.00 | $6.45 |
Technical Indicators
Market Signals| Indicator | MNPR | KOPN |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 60.60 |
| Support Level | $51.71 | $2.13 |
| Resistance Level | $67.90 | $6.45 |
| Average True Range (ATR) | 5.65 | 0.60 |
| MACD | 0.27 | -0.09 |
| Stochastic Oscillator | 68.24 | 39.33 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.